Lasofoxifene tartrate is primarily used in the treatment and prevention of osteoporosis in postmenopausal women. It works by acting as a selective estrogen receptor modulator (SERM), which helps to maintain bone density and reduce the risk of fractures. Additionally, it has shown potential in reducing the risk of invasive breast cancer in this population. The compound is also being investigated for its efficacy in managing vaginal atrophy, a common condition in postmenopausal women characterized by dryness and discomfort. Its ability to mimic estrogen's beneficial effects on bone and breast tissue, while avoiding negative effects on the uterus, makes it a valuable therapeutic option in postmenopausal health management.